MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

DownloadDownload image
Non Us$140,100K US$285,300K Eylea Net ProductSales$576,900K ELYEAHD$506,300K Other Products$3,100K Inmazeb-US$9,350K Evkeeza-US$47,300K Praluent Net ProductSales-US$72,200K LIBTAYONet Product Sales$425,400K ELYEAHDAnd EYLEA-US$1,083,200K Product And ServiceOther$238,600K Collaboration Revenue$1,970,900K Product$1,674,800K Other income(expense), net$176,000K Revenue from contractwith customer$3,884,300K Total other income(expense)$163,800K Income from operations$879,900K Interest expense$12,200K Total expenses$3,004,400K Income before incometaxes$1,043,700K Cost of goods sold andof collaboration...$265,900K Cost of goods sold andof collaboration...$318,700K Selling, general, andadministrative$775,000K Acquired in-processresearch and development$18,700K Research and development$1,626,100K Gain (loss) onforeign currency...$1,400K Unrealized gain on debtsecurities$7,100K Net income$844,600K Income tax expense$199,100K Comprehensive income$853,100K
Income Statement
source: myfinsight.com
REGN_BIG copy-svg-svg-svg

REGENERON PHARMACEUTICALS, INC. (REGN)

REGN_BIG copy-svg-svg-svg

REGENERON PHARMACEUTICALS, INC. (REGN)